Table 1.

Baseline characteristics of the patients.

Variable		N = 60
Gender [n (%)]	n	60
	Male	50 (83)
	Female	10 (17)
Age (years)	Median	61
	Range	23–79
Age [n (%)]	n	60
	<65 years	36 (60)
	65–69 years	14 (23)
	≥70 years	10 (17)
ECOG-PS [n (%)]	n	60
	0	9 (15)
	1	20 (33)
	2	31 (52)
Tobacco status [n (%)]	n	60
	Nonsmoker	12 (20)
	Current or former smoker	48 (80)
Primary tumor localization [n (%)]	n	60
	Oropharynx	23 (40)
	Oral cavity	17 (28)
	Hypopharynx	12 (20)
	Larynx	7 (12)
	Unknown	1 (2)
Histologic type [n (%)]	n (not specified or missing)	38 (22)
	Well differentiated	8 (21)
	Moderately differentiated	23 (60)
	Poorly differentiated	7 (18)
Initial treatment [n (%)]	n	60
	Neoadjuvant chemotherapy + Surgery	5 (8)
	Neoadjuvant chemotherapy + Surgery + CRT	1 (2)
	Neoadjuvant chemotherapy + CRT (cetuximab)	5 (8)
	Surgery	9 (15)
	Surgery + RT	6 (10)
	Surgery + CRT (platin-based)	15 (25)
	Surgery + CRT (other)	7 (12)
	RT alone	2 (3)
	CRT (cisplatin)	3 (5)
	CRT (cetuximab)	2 (3)
	No prior treatment	5 (8)
Local treatment for first relapse with a curative intent [n (%)]	Surgery	11 (18)
	Reirradiation	4 (7)
Tumor extension at baseline [n (%)]	n	60
	Loco regional only	33 (55)
	Loco regional and metastatic	13 (22)
	Metastatic only	14 (23)
Characteristics of relapse [n (%)]	n	60
	Relapse in RT field	38 (63)
	Relapse after platinum-based regimen (neoadjuvant, CRT)	29 (48)
Platinum free interval before baseline [n (%)]	n	29
	<3 months	11 (38)
	3–5.9 months	3 (10)
	≥6 months	15 (52)
Chemotherapy ineligibility [n (%)]	n	60
	Cisplatin	55 (92)
	5-FU	34 (57)

ECOG PS, Eastern Cooperative Oncology Group Performance Status; CRT, concurrent chemoradiotherapy; RT, radiotherapy.